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Objective: We evaluate early results of bovine jugular vein conduits in the pulmo-
nary outflow.
Methods: Between April 2000 and September 2001, 31 conduits were placed in the
outflow of the right ventricle. Patients who received a conduit as a staged surgical
procedure were excluded (n  3). Implantation age ranged from 0 to 21 years
(median, 3.4 years). Conduit diameter ranged from 12 to 20 mm (median, 14 mm).
Transthoracic echocardiography was performed at discharge and 3 months after
surgery. Patients with significant pulmonary regurgitation and/or stenosis underwent
cardiac catheterization.
Results: Four patients died during the follow-up period. Three deaths were unrelated
to the conduit. One death was related to the complete thrombosis of the conduit. At
3 months evaluation, pulmonary valve regurgitation was absent or trivial in 19, mild
in 2 and severe in 3 of 24 survivors. Four patients had nonfatal conduit-related
complications. A transient thrombus formation within 1 leaflet was noted postop-
eratively in a patient with a moderate pulmonary regurgitation. Three patients
required reoperation 3 to 5.8 months after the implantation for conduit failure
(mean, 4.3 months). Cardiac catheterization before replacement revealed an aneu-
rysmal dilation of the conduit below a severe stenosis of the pulmonary bifurcation
due to important neointimal proliferation.
Conclusions: Early failure of bovine jugular vein valved conduits can occur because
of exaggerated intimal proliferation or thrombotic process within the conduit.
Because of these complications, close echocardiographic follow-up is mandatory
during the first weeks after implantation.
In a great variety of congenital heart diseases, a valved conduit is requiredto reestablish the continuity between the right ventricle and the pulmonaryartery bifurcation.1,2 While widely used, conduits made with woven syn-thetic tubes as supportive housing for a biological valve (porcine aorticvalve, bovine pericardium, or homograft) are not ideal because of rapidcomplications in children.3-6 These include valvar dysfunction, calcification
of the valve, and accumulation of fibrous peel within the synthetic conduit and lead
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to progressive stenosis of the conduit. The life span of these
conduits depends largely on the biological origin of the
valve. A conduit using bovine jugular vein, which contains
a natural trileaflet valve (Contegra, Venpro, Medtronic),
was introduced in mid-2000. Preliminary animal studies
have shown that this totally integrated valved conduit has
good biocompatibility and excellent hemodynamic proper-
ties.7-9 This conduit is also available in various diameters,
from 12 to 22 mm, making it suitable for implantation from
early infancy to adulthood. These properties have led to an
extension of its use. However, no data are yet available on
the performance of these conduits in the clinical setting. The
purpose of this single-center study was to investigate the
early performance of this new conduit.
Methods
Patient Population
We reviewed the records of all patients who underwent placement
of a Contegra conduit (Venpro, Medtronic) for the establishment
of the continuity between the right ventricle and the pulmonary
arteries between April 2000 and September 2001. Diagnoses were
established in the cardiac unit with echocardiography and/or an-
giography. Operations done in a single institution by a single
operator were included. During that period, 31 conduits were
placed. Patients with total repair were eligible (28/31). Three
patients with a pulmonary atresia and a ventricular septal defect
were excluded from the study because the ventricular septal defect
was not closed at the time of conduit insertion. There were 16 men
(57.1%) and 12 women (42.9%). The median age at operation was
3.4 years (range, 0-21.1 years). Bovine jugular vein conduits were
implanted in a variety of congenital heart diseases (Table 1). The
diameter of the conduit at the time of implantation ranged from 12
mm to 20 mm (14.8  2.9 mm; median, 14 mm). Six conduits
were stented (21.4%). Tables 2A and 2B summarize the clinical
characteristics of the included patients and conduit specifications
together with age range. Sixteen out of the 28 eligible patients
(57.1%) had undergone at least 1 previous cardiac operation (Table
3).
Surgical Repair
The operations were performed through a median sternotomy.
Conventional cardiopulmonary bypass was used with double ve-
nous canulation and cardioplegia. The conduit was anastomozed to
an infundibulotomy. Enlargement of the pulmonary artery bifur-
cation was performed as needed. Any associated defects were
repaired before conduit insertion (Table 4).
Follow-up
Echocardiographic evaluation was carried out in all surviving
patients and examined in the immediate postoperative period and
reexamined with a transthoracic approach 3 months postopera-
tively. All studies were reviewed in order to assess the presence of
pulmonary regurgitation and to determine the mean valve gradient.
The pulmonary regurgitation was classified as none (grade 0),
trivial (grade 1), mild (grade 2), moderate (grade 3), or severe
(grade 4) with regard to features of the jet with pulsed flow
Doppler in short-axis parasternal view.10 Conduit stenosis was
assessed by measuring the peak velocity through the valve with
continuous-wave Doppler technique. All patients with severe pul-
monary regurgitation and/or significative obstruction of the right
ventricular outflow tract were catheterized.
Data Collection and Statistical Analysis
Preoperative and postoperative data were collected at retrospective
review of patients’ records. Data are presented as the mean  the
standard deviation. Early events were defined as events that oc-
curred before hospital discharge or within 30 days of operation if
the patient was discharged before this duration. Event-free survival
distribution was estimated using the actuarial method. The
overall cardiac events including death, severe pulmonary regur-
gitation, and conduit thrombosis were considered relevant for
this analysis.
Results
Mortality and Survival
There were 4 deaths (14.3%) during the follow-up period, 3
early deaths, and 1 late death. One patient died of pulmo-
nary problems at the age of 3 months following a gastro-
enteral operation. Another patient with a truncus arteriosus
and a regurgitant truncal valve died of infection in the early
course after the operation. This child had a severe broncho-
pulmonary dysplasia that delayed his discharge from the
cardiac intensive care unit. The third patient died of severe
pulmonary disease secondary to a premature birth. This
infant had a truncus arteriosus with an interrupted aortic
arch without 22q11 microdeletion. His cardiac disease was
completely repaired early at the age of 15 days when he
weighed 2300 g. None of these 3 deaths were directly
related to the conduit. The last death occurred in a patient
with a tetralogy of Fallot associated with a complete atrio-
ventricular canal and a trisomy 21. This patient was com-
pletely repaired at a first procedure at the age of 16 months
and rapidly discharged without any medication. Echocar-
TABLE 1. Patient characteristics
Cardiovascular disease No. %
Pulmonary atresia/VSD 6 21.4
Tetralogy of Fallot 5 17.9
With AVC 1
Truncus arteriosus 9 32.1
Type 1 7
Type 4 2
Aortic valve stenosis 4 14.3
Isolated 2
With VSD 1
Coarctation of the aorta 1
Absent pulmonary valve syndrome 2 7.1
Complex transposition 2 7.1
With pulmonary stenosis 1
With pulmonary atresia 1
VSD, Ventricular septal defect; AVC, atrioventricular canal.
Boudjemline et al Surgery for Congenital Heart Disease
The Journal of Thoracic and Cardiovascular Surgery ● Volume 126, Number 2 491
CH
D
diodiography at discharge showed a trivial pulmonary re-
gurgitation and a moderate elevation of the systolic ventric-
ular pressure at 40 mm Hg. Fourteen days after the
operation, he was found dead by his mother. The anato-
mopathologic study revealed a complete thrombosis of the
12-mm conduit with multiple pulmonary embolisms and
infarcts. Abundant chylothoracic effusion and signs of liver
congestion were also present.
Early Dysfunction
One patient with a 14-mm conduit implanted to correct a
complex transposition of the great artery had a grade 3
pulmonary regurgitation postoperatively. This regurgitation
was caused by a thrombus formation within 1 leaflet. After
a 1-week course of intravenous heparin, the thrombus dis-
appeared and the patient was discharged. The echocardiog-
raphy at discharge showed a trivial regurgitation of the
implanted valve.
Conduit replacements were performed in 3 patients at 3,
4, and 5.8 months after the initial insertion of a 12-mm
conduit (mean, 4.3 months). Echocardiography showed a
severe dilation of the right ventricle (RV) secondary to
massive pulmonary regurgitation, and at least iso-systemic
systolic RV hypertension. These patients were catheterized
before surgery. The catheterization study confirmed the
echocardiographic data showing dilated and dysfunctioning
RV, and an aneurysmal dilation of the conduit below a
severe stenosis of the pulmonary bifurcation. The mean
diameter of the conduit was measured angiographically at
20 mm (Figure 1). All these data were confirmed during
surgical replacement of these failing conduits. Mascro-
scopic examination of the retrieved conduit showed a non-
functioning valve (Figure 2). A fibrinous tissue was cover-
ing 2 of the 3 leaflets. This tissue was easily retrieved
without any damage to the valve. No valvar calcification
was found macroscopically and histologically. Histological
TABLE 2A. Conduit specifications
Conduit sizes 12 mm 14 mm 16 mm 18 mm 20 mm
No. (%) 11 (39.3) 6 (21.4) 4 (14.3) 3 (10.7) 4 (14.3)
Mean age at implantation
(range)
4 mo (0.4-16.1) 1.9 y (0.6-4) 2.4 y (1-5.6) 7.5 y (5.5-10.3) 12.1 y (5.8-21.1)
Stented conduits (%) 3 (27.3) 2 (33.3) 0 0 1 (25)
TABLE 2B. Age categories
Age categories No. %
0-12 mo 14 50
12-24 mo 4 14.3
2-5 y 2 7.1
5-10 y 5 17.9
10 y 3 10.7
TABLE 3. Operative data
Previous surgery No.
Blalock-Taussing shunt 7
RVOT reconstruction with conduit insertion 10
LV to Ao conduit 1
Unifocalization of the pulmonary artery 3
Valvuloplasty 4
Surgical 1
Transcatheter 3
VSD closure 9
RV to PA conduit replacement 1
Crafoord procedure 1
Ductus arteriosus ligation 5
Konno procedure 1
Pulmonary transannular patch 2
ASD closure 1
Enlargement of the aorta and ductal tissue resection 1
RVOT, Right ventricular outflow tract; LV, left ventricle; Ao, aorta; VSD-
ventricular septal defect; RV, right ventricle; PA, pulmonary artery; ASD,
atrial septal defect.
TABLE 4. Concomitant procedures
Concomitant procedures No.
Reconstruction of the
pulmonary artery
bifurcation
5
Proximal/distal elargement of
the pulmonary arteries
5
Size reduction of the
pulmonary arteries
2
VSD closure 10
Ligation of BT shunt 7
Ligation of MAPCAs 2
Pacemaker implantation 1
Creation of an ASD 4
Ross procedure 4
Bentall 1
Konno 5
Conduit replacement 10
Plasty of truncal valve 1
VSD, Ventricular septal defect; BT, Blalock-Taussig; MAPCA, major aor-
topulmonary collateral artery; ASD, atrial septal defect.
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study showed an important fibrointimal proliferation in the
inside layer of the xenografts predominantly in the pulmo-
nary anastomosis that obstructed the lumen. At this site, the
orifice measured 0.5 cm. At the outside layer, a uniformly
myofibroblastic reaction with a collagen formation was
found (Figure 3). Within this formation, a mild foreign body
reaction was also present. From the middle part of the
conduit to the ventricular anastomosis, a histiocytic reaction
infiltrated and partially digested the external part of the
prosthesis. No host cells covered the valvular leaflets. No
endothelial proliferation was observed in the lumen of xeno-
grafts.
Reoperations consisted of replacement of the conduits by
a porcine aortic valve (Labcor) and an enlargement of the
pulmonary bifurcation by a pericardium patch. Two of these
patients are now facing problems of residual proximal pul-
monary artery stenosis. Actuarial survival curve for adverse
cardiac events is shown on Figure 4.
Conduit Function
Doppler echocardiographic evaluation before discharge
showed no or trivial regurgitation in 20 patients (83.3%), a
mild valve regurgitation in 4 patients (16.7%), and moderate
or severe regurgitation in none. The peak velocity across the
valve at that time was less than 2 m/s in 17 out 24 patients,
and between 2 and 3 m/s in 7 patients. Echocardiographic
follow-up was obtained in all survivors. Results are sum-
marized in Table 5.
Discussion
The surgical management of congenital heart diseases in-
volving the right ventricular outflow tract has largely
evolved over the past decade.1-6 However, the reconstruc-
tion of the right ventricular outflow tract remains a problem.
Currently, the continuity between the RV and the pulmo-
nary artery is established by the interposition of a prosthetic
conduit. Various conduits are commercially available, but
the perfect substitute has yet to be found because of non-
rare complications during the follow-up. Recently, a new
conduit using a bovine jugular vein that contains a natural
valve with a sinus has been introduced.7-9,11 The leaflets of
the valve are extremely thin and mobile. The venous wall in
form of a conduit is soft and ideal for suturing and usually
does not necessitate any artifice or any interposition of other
materials to make the anastomoses with the RV and the
pulmonary artery. Moreover, its availability in various di-
ameters from 12 to 22 mm makes its use possible in neo-
nates. Thereby, it became popular and is now used in our
institution and worldwide. Early and long-term functions of
this valve are, however, presently unknown.
Here we described the function of bovine jugular vein
conduit within 3 months after its insertion. Valvar compe-
tence at 3 months is excellent, with nearly 80% of patients
with absent or trivial pulmonary regurgitation. The early
complication reported here, however, balanced these good
results. Indeed, 1 death was directly related to the Contegra
conduit and could have been avoided. The patient was
discharged from the hospital without any anticoagulant or
platelet anti-aggregant therapy. This resulted in the progres-
sive thrombosis of the valve, which was responsible for (1)
elevation of right pressures resulting in cardiac liver and
pleural effusion and (2) multiple emboli with pulmonary
infarcts. Additionally, a thrombus formation was observed
on a valvular leaflet in another patient. Heparinization of the
patient, however, led to the complete resolution of the
thrombus. No anticoagulant therapy is recommended after
the insertion of this type of conduit. However, biological
Figure 1. Angiograms (4-chamber view on the left and lateral view on the right) showing the aneurysmal dilation
of the Contegra conduit before a severe stenosis of the pulmonary bifurcation 3 months after insertion.
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implants crosslinked with glutaraldehyde are potentially
thrombogenic.8,9,12 Indeed, collagen molecules contained in
biologic materials have many amino groups that are posi-
tively charged and can accumulate negatively charged plate-
lets.13 Glutaraldehyde, by binding with the basic amino
acids, creates an impaired balance between positive and
negative charge in favor of negative charges.14 Thus, glu-
taraldehyde-pretreated implants become negatively
charged, repulse platelets and, therefore, are less thrombo-
genic.15 However, glutaraldehyde has been reported to de-
lay the endothelialization that reduces thrombogenicity of
cardiovascular implants.16-18 Indeed, residual glutaralde-
hyde released from the implant long after insertion hinders
host cells to colonize the luminal layer exposing the implant
to thrombogenic process.8,9,19 Chang and colleagues9 re-
cently showed no endothelialization of glutaraldehyde-pre-
treated grafts 6 months after implantation in a canine model.
Therefore, we now prescribe an anti-aggregant therapy in all
patients for at least 6 to 12 months after the implantation.
After this time, we discontinue the treatment, hypothesizing
that endothelialization of the implant is complete and that
thrombus formation is unlikely to occur.
Three other patients with a 12-mm valve had to be
reoperated for an early failing of their conduit. With previ-
ously used conduits, early failures have been described not
infrequently, in particular when small valves were inserted
in young children.20 The causes and the mechanisms of this
failure remain unclear. It has been suggested that geometric
distortion as well as immunologic rejection may be in-
volved.4,21 The aneurysmal dilation of the conduit is more
likely to occur in small conduits because these are im-
planted in neonates and young infants who have hypoplastic
pulmonary arteries, making the repair particularly difficult.
This would probably have been avoided by the use of a
supported conduit that had 2 external rings. Out of the seven
12-mm conduits we implanted, 4 were not supported and 3
were supported. Presently, none of the supported valved
conduits failed. However, the ring could compress the cor-
Figure 2. Macroscopic images of the conduit retrieved: A, Longitudinal view of a bovine jugular vein. The
ventricular anastomosis has a normal size whereas the pulmonary anastomosis (on the right) has a tight stenosis.
B, Valve leaflet after retrieval of a fibrinous tissue shown in the upper right. C, Inner front view of the stenosed
pulmonary artery anastomosis. D, Outer front view of the pulmonary artery anastomosis.
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onary artery, particularly in neonates and infants, making
their use more delicate in this population. The stenosis of
the pulmonary artery bifurcation could result from an inap-
propriate reconstruction. Even if it is unlikely, particular
attention should be made when anastomosing the pulmo-
nary arteries to the conduit to avoid further stenosis of the
Figure 3. Photomicrographs of longitudinal section of the bovine jugular vein conduit 4 months postoperatively. A,
Valve leaflets. B, Ventricular anastomosis. C, Pulmonary anastomosis.
Figure 4. Actuarial survival curve of adverse cardiac events.
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pulmonary artery bifurcation. More astonishingly, the pres-
ence of inflammatory tissue located predominantly at the
anastomosis underlines the possibility of an immunologic
rejection. Cytotoxicity of residual glutaraldehyde may in-
duce a foreign-body reaction and explain early bovine jug-
ular vein failure.8,9,22 However, this reaction was limited in
our study and did not explain the obstruction of the con-
duits. A pathological intimal proliferation predominantly
located at the pulmonary anastomosis was present at the
inside layer of the conduit, explaining its obstruction. No
data are available in the literature to explain this phenom-
enon, but the occurrence in only glutaraldehyde-fixed grafts
is questionable. Fibrointimal formation has been described
in woven synthetic conduits and was attributed to fenestra-
tions within the peel.23-25 Crosslinking that creates a net-
work between the molecules of collagen might induce such
fenestrations. Moreover, the proliferation predominated at
the site of suture line. Chemical interactions between suture
material and glutaraldehyde or cellular damages during su-
turing aggravated by glutaraldehyde cytotoxicity might be
involved in intimal hyperplasia.
The occurrence of early failure in only 12-mm conduit is
also questionable. Is the intimal proliferation normal or
abnormal regarding the size of the conduit? Thus, similar
intimal growth would lead to obstruction and dilation of the
conduit in small conduits, whereas no adverse effect would
be noticed with bigger conduits. And/or are neonates more
likely to develop inappropriate reaction in response to
crosslinking agent? Several crosslinking agents are pres-
ently under investigation to increase the life span of these
conduits.
The uncontrolled dilation of the conduit is a major con-
cern in terms of valvar competence, but shows that this
conduit can increase in diameter with time under certain
hemodynamic conditions. Because leaflets inside the con-
duit have excess tissue, the competence of the valve is
preserved in moderately dilated conduits. However, no real
growth with cellular proliferation is possible with devital-
ized conduits, and progressive dilation would certainly lead
to significant pulmonary regurgitation. Nevertheless, if
long-term study confirms this feature, this would lead to
reduction of reoperation for conduit replacement because of
somatic growth.
Conclusion
The use of bovine jugular vein conduit has gained interest
recently because of its intrinsic qualities. Early failure de-
scribed in this report emphasizes the need for (1) controlling
the adequacy of the distal anastomosis on the pulmonary
artery bifurcation particularly in small patients and (2) care-
ful rinsing of the conduit prior to its insertion to remove the
glutaraldehyde. It also underlined the importance to pre-
scribe an anti-aggregant therapy after the implantation to
avoid early thrombosis of the conduit. Finally, long-term
studies are obviously needed to ascertain safety, efficacy,
and durability of the conduit.
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